On April 26, 2021, Philips provided an important update regarding proactive efforts to address identified issues with a component in certain products of our Sleep & Respiratory Care portfolio.
Philips has determined from user reports and testing that there are possible risks to users related to the sound abatement foam used in certain of Philips sleep and respiratory care devices currently in use. The risks include that the foam may degrade under certain circumstances, influenced by factors including use of unapproved cleaning methods, such as ozone*, and certain environmental conditions involving high humidity and temperature. Philips’ recently launched next-generation CPAP platform, DreamStation 2 is not affected.
To date, Philips have not received reports of serious patient harm related to this issue.
Philips takes this matter very seriously, and is working to address this issue for our customers and patients who rely on our sleep and respiratory care solutions.
If you have any concerns or questions, please call us on 1300 375 384 to assist.